Back to search

Article

Biologic agents for rheumatic diseases in the break of COVID-19: friend or foe?

2020-09-03

Abstract excerpt

<h4>Background</h4> The recent outbreak of COVID-19 has raised concerns in the rheumatology community about the management of immunosuppressive patients diagnosed with inflammatory rheumatic diseases. It is not clear whether the use of biologic agents may suppose a risk or protection against SARS-CoV2 infection however, it has been suggested that severe respiratory forms of COVID-19 occur as result of exacerbated...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
66236bb3-f5de-5901-b6ed-135a203bc82f
DOI
10.1101/2020.09.01.20184333
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Biologic agents for rheumatic diseases in the break of COVID-19: friend or foe?DOI 10.1101/2020.09.01.20184333
Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in ScotlandSemantic proximity
Does Biological Therapy Protect against Severe COVID-19?Semantic proximity
Clinical Features of Rheumatic Patients with Biologics Treatment Infected with COVID-19 in ChinaSemantic proximity
Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugsSemantic proximity
No Increased Lethality in Covid-19 in Patients with Inflammatory Rheumatic Diseases Compared to the General Population - a Comparison of Two German Registries -Semantic proximity
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugsSemantic proximity
How Did COVID-19 Pandemic Affect Rheumatology Out-Patients Practice? A Single-Center Experience from TurkeySemantic proximity
Covid 19 Infection in Patients with Rheumatic Immune-Mediated Diseases in a Single University Hospital. Matched Case-Control Study and Literature Review.Semantic proximity
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platformSemantic proximity
A Prospective Longitudinal Study Evaluating The Influence of Immunosuppressives and Other Factors On COVID-19 in Autoimmune Rheumatic DiseasesSemantic proximity
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort studySemantic proximity
Factors Associated with COVID-19 Breakthrough Infection in the Pre-Omicron Era Among Vaccinated Patients with Rheumatic Diseases: A Cohort StudySemantic proximity
Select a neighboring publication to make it the new centre.